PMID- 33644101
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210303
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 8
DP  - 2021
TI  - Next Generation Sequencing in Cytopathology: Focus on Non-Small Cell Lung Cancer.
PG  - 633923
LID - 10.3389/fmed.2021.633923 [doi]
LID - 633923
AB  - Molecular cytopathology is a rapidly evolving field embracing both conventional 
      microscopy and molecular pathology. Its growing popularity stems from the fact 
      that in many types of advanced cancers, including non small cell lung cancer 
      (NSCLC), cytological samples often constitute the only available specimens for 
      morphomolecular analysis. Indeed, non formalin fixed and paraffin embedded (FFPE) 
      cytological samples feature a higher quality of extracted nucleic acids than 
      histological specimens. However, because of the growing complexity of molecular 
      testing, several efforts should be made to validate the analytical performance of 
      the wide array of currently available molecular technologies, including next 
      generation sequencing (NGS). This technology has the terrific advantage of 
      allowing simultaneous detection of scores of predictive biomarkers even in 
      low-input DNA/RNA specimens. Here, we briefly review the role of the modern 
      cytopathologist in the morphomolecular diagnosing of advanced stage NSCLC and the 
      adoption of NGS in conventional cytopreparations (cell blocks, direct smears, and 
      liquid-based cytology) and supernatants.
CI  - Copyright (c) 2021 Pisapia, Pepe, Iaccarino, Sgariglia, Nacchio, Conticelli, 
      Salatiello, Tufano, Russo, Gragnano, Girolami, Eccher, Malapelle and Troncone.
FAU - Pisapia, Pasquale
AU  - Pisapia P
AD  - Department of Public Health, University of Naples Federico II, Naples, Italy.
FAU - Pepe, Francesco
AU  - Pepe F
AD  - Department of Public Health, University of Naples Federico II, Naples, Italy.
FAU - Iaccarino, Antonino
AU  - Iaccarino A
AD  - Department of Public Health, University of Naples Federico II, Naples, Italy.
FAU - Sgariglia, Roberta
AU  - Sgariglia R
AD  - Department of Public Health, University of Naples Federico II, Naples, Italy.
FAU - Nacchio, Mariantonia
AU  - Nacchio M
AD  - Department of Public Health, University of Naples Federico II, Naples, Italy.
FAU - Conticelli, Floriana
AU  - Conticelli F
AD  - Department of Public Health, University of Naples Federico II, Naples, Italy.
FAU - Salatiello, Maria
AU  - Salatiello M
AD  - Department of Public Health, University of Naples Federico II, Naples, Italy.
FAU - Tufano, Rossella
AU  - Tufano R
AD  - CEINGE Biotecnologie Avanzate, Naples, Italy.
FAU - Russo, Gianluca
AU  - Russo G
AD  - Department of Public Health, University of Naples Federico II, Naples, Italy.
FAU - Gragnano, Gianluca
AU  - Gragnano G
AD  - Department of Public Health, University of Naples Federico II, Naples, Italy.
FAU - Girolami, Ilaria
AU  - Girolami I
AD  - Division of Pathology, Central Hospital Bolzano, Bolzano, Italy.
FAU - Eccher, Albino
AU  - Eccher A
AD  - Department of Pathology and Diagnostics, University and Hospital Trust of Verona, 
      Verona, Italy.
FAU - Malapelle, Umberto
AU  - Malapelle U
AD  - Department of Public Health, University of Naples Federico II, Naples, Italy.
FAU - Troncone, Giancarlo
AU  - Troncone G
AD  - Department of Public Health, University of Naples Federico II, Naples, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210211
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC7904874
OTO - NOTNLM
OT  - NSCLC
OT  - cell block
OT  - cytopathology
OT  - fine needle aspiration
OT  - liquid based cytology
OT  - molecular cytopathology
OT  - smear
COIS- UM reports personal fees (as speaker bureau or advisor) from Boehringer 
      Ingelheim, AstraZeneca, Roche, MSD, Amgen, and Merck, unrelated to the current 
      work. GT reports personal fees (as speaker bureau or advisor) from Roche, MSD, 
      Pfizer, and Bayer, unrelated to the current work. The remaining authors declare 
      that the research was conducted in the absence of any commercial or financial 
      relationships that could be construed as a potential conflict of interest.
EDAT- 2021/03/02 06:00
MHDA- 2021/03/02 06:01
PMCR- 2021/02/11
CRDT- 2021/03/01 05:39
PHST- 2020/11/26 00:00 [received]
PHST- 2021/01/19 00:00 [accepted]
PHST- 2021/03/01 05:39 [entrez]
PHST- 2021/03/02 06:00 [pubmed]
PHST- 2021/03/02 06:01 [medline]
PHST- 2021/02/11 00:00 [pmc-release]
AID - 10.3389/fmed.2021.633923 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2021 Feb 11;8:633923. doi: 10.3389/fmed.2021.633923. 
      eCollection 2021.